newsfilter
← Latest News
Business Wire·

Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

Three Phase 3 topline Rubraca data readouts expected in 2022 Initial data from LuMIERE study of targeted radiotherapy candidate FAP-2286 also expected in 2022 Improved balance sheet complements ongoing focus on cost control Clovis Oncology, Inc